Mr. Whitman has served as a member of the Board since 2019. He leads and governs mission-driven organizations in business, national service, and civil society. Since 2019 he serves as CEO, Colmar Holdings (private); Board of Directors, Amicus Therapeutics; Board of Directors, Omega Healthcare Investors; Board of Advisors, Secretary of Defense (Reserve Forces Policy Board); and Board of Trustees, The Lovett School. Formerly in business 1988-2008, he served as CEO, HMA (Fortune 500, sold); CFO, Triad Hospitals (Fortune 500, sold); President, Deerfield Healthcare (private, sold); VP, Almost Family; and Investment Banker, Morgan Stanley. Concurrently in national service 1985-2018, he served as a reserve officer of the U.S. Marine Corps including active duty 1985-1988 and 2009-2018, led five combat deployments, was Commanding General of 4th Marine Division and Marine Forces Reserve, served with the Secretary of Defense, and completed uniformed service as a Major General and the Corps’ senior reservist. For civil society, he has served on the Boards of the Federation of American Hospitals, Toys for Tots Foundation, Marine Corps University, and on the Founders Group of the National Museum of the Marine Corps. He is a graduate of Harvard Business School, Army War College, and Dartmouth College.
Mr. Whitman serves as member of the Nominating and Governance Committee and as member of the Audit and Compliance Committee.
What is Burke W. Whitman's net worth?
The estimated net worth of Burke W. Whitman is at least $240,076.06 as of September 1st, 2021. Mr. Whitman owns 25,034 shares of Amicus Therapeutics stock worth more than $240,076 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Whitman may own. Learn More about Burke W. Whitman's net worth.
How do I contact Burke W. Whitman?
Has Burke W. Whitman been buying or selling shares of Amicus Therapeutics?
Burke W. Whitman has not been actively trading shares of Amicus Therapeutics over the course of the past ninety days. Most recently, on Monday, November 1st, Burke W. Whitman bought 1,500 shares of Amicus Therapeutics stock. The stock was acquired at an average cost of $10.49 per share, with a total value of $15,735.00. Learn More on Burke W. Whitman's trading history.
Who are Amicus Therapeutics' active insiders?
Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.
Are insiders buying or selling shares of Amicus Therapeutics?
During the last year, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 350,095 shares worth more than $4,532,405.15. The most recent insider tranaction occured on November, 6th when CEO Bradley L Campbell sold 7,901 shares worth more than $98,762.50. Insiders at Amicus Therapeutics own 2.2% of the company.
Learn More about insider trades at Amicus Therapeutics. Information on this page was last updated on 11/6/2024.
